{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:11:05Z","timestamp":1794035465637,"version":"4.8.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008392","name":"Sundhed og Sygdom, Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["7016-00022"],"award-info":[{"award-number":["7016-00022"]}],"id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008392","name":"Sundhed og Sygdom, Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["9060-00023B"],"award-info":[{"award-number":["9060-00023B"]}],"id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008392","name":"Sundhed og Sygdom, Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["7016-00022"],"award-info":[{"award-number":["7016-00022"]}],"id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007605","name":"Aarhus Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Danish Regions\u2019 Medicine and Treatment Fund"},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1038\/s41591-022-02023-7","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T12:03:30Z","timestamp":1666008210000},"page":"2424-2435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":162,"title":["Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a, randomized trial"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3787-0259","authenticated-orcid":false,"given":"Jesper D.","family":"Gunst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie H.","family":"Pahus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2850-6586","authenticated-orcid":false,"given":"Miriam","family":"Ros\u00e1s-Umbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Na","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0698-9385","authenticated-orcid":false,"given":"Thomas","family":"Benfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isik S.","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Mohey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Klastrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane H.","family":"Schleimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"St\u00f8vring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-8147","authenticated-orcid":false,"given":"Paul W.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie N.","family":"Kinloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3217-4713","authenticated-orcid":false,"given":"Dennis C.","family":"Copertino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7038-5597","authenticated-orcid":false,"given":"Adam R.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winiffer D. Conce","family":"Alberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke D.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6750-2318","authenticated-orcid":false,"given":"Maria C.","family":"Puertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline D.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5496-8090","authenticated-orcid":false,"given":"Christos J.","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-2129","authenticated-orcid":false,"given":"Javier","family":"Martinez-Picado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8157-1037","authenticated-orcid":false,"given":"Zabrina L.","family":"Brumme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4470-1231","authenticated-orcid":false,"given":"R. Brad","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tolstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0592-8564","authenticated-orcid":false,"given":"Michel C.","family":"Nussenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Caskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9107-2023","authenticated-orcid":false,"given":"Ole S.","family":"S\u00f8gaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"2023_CR1","doi-asserted-by":"publisher","first-page":"eaaw5589","DOI":"10.1126\/scitranslmed.aaw5589","volume":"11","author":"MR Abrahams","year":"2019","unstructured":"Abrahams, M. R. et al. The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Sci. Transl. Med. 11, eaaw5589 (2019).","journal-title":"Sci. Transl. Med."},{"key":"2023_CR2","doi-asserted-by":"publisher","first-page":"e18889","DOI":"10.7554\/eLife.18889","volume":"5","author":"J Brodin","year":"2016","unstructured":"Brodin, J. et al. Establishment and stability of the latent HIV-1 DNA reservoir. elife 5, e18889 (2016).","journal-title":"elife"},{"key":"2023_CR3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/infdis\/jiz563","volume":"221","author":"GE Martin","year":"2020","unstructured":"Martin, G. E. et al. Levels of human immunodeficiency virus DNA are determined before ART initiation and linked to CD8 T-cell activation and memory expansion. J. Infect. Dis. 221, 1135\u20131145 (2020).","journal-title":"J. Infect. Dis."},{"key":"2023_CR4","doi-asserted-by":"publisher","first-page":"E8958","DOI":"10.1073\/pnas.1802028115","volume":"115","author":"BR Jones","year":"2018","unstructured":"Jones, B. R. et al. Phylogenetic approach to recover integration dates of latent HIV sequences within-host. Proc. Natl Acad. Sci. USA 115, E8958\u2013E8967 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2023_CR5","doi-asserted-by":"publisher","first-page":"e1008378","DOI":"10.1371\/journal.ppat.1008378","volume":"16","author":"K Brooks","year":"2020","unstructured":"Brooks, K. et al. HIV-1 variants are archived throughout infection and persist in the reservoir. PLoS Pathog. 16, e1008378 (2020).","journal-title":"PLoS Pathog."},{"key":"2023_CR6","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","volume":"1","author":"TA Rasmussen","year":"2014","unstructured":"Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial. Lancet HIV 1, e13\u2013e21 (2014).","journal-title":"Lancet HIV"},{"key":"2023_CR7","first-page":"343","volume":"30","author":"JZ Li","year":"2016","unstructured":"Li, J. Z. et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 30, 343\u2013353 (2016).","journal-title":"AIDS"},{"key":"2023_CR8","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.jve.2020.100004","volume":"6","author":"EDMB Kroon","year":"2020","unstructured":"Kroon, E. D. M. B. et al. A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. J. Virus Erad. 6, 100004 (2020).","journal-title":"J. Virus Erad."},{"key":"2023_CR9","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","volume":"3","author":"S Leth","year":"2016","unstructured":"Leth, S. et al. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial. Lancet HIV 3, e463\u2013e472 (2016).","journal-title":"Lancet HIV"},{"key":"2023_CR10","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2666-5247(21)00239-1","volume":"3","author":"H Gruell","year":"2022","unstructured":"Gruell, H. et al. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. Lancet Microbe 3, e203\u2013e214 (2022).","journal-title":"Lancet Microbe"},{"key":"2023_CR11","doi-asserted-by":"publisher","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","volume":"11","author":"OS S\u00f8gaard","year":"2015","unstructured":"S\u00f8gaard, O. S. et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 11, e1005142 (2015).","journal-title":"PLoS Pathog."},{"key":"2023_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(05)67098-5","volume":"366","author":"G Lehrman","year":"2005","unstructured":"Lehrman, G. et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366, 549\u2013555 (2005).","journal-title":"Lancet"},{"key":"2023_CR13","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1097\/QAD.0b013e3282fd6df4","volume":"22","author":"NM Archin","year":"2008","unstructured":"Archin, N. M. et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 22, 1131\u20131135 (2008).","journal-title":"AIDS"},{"key":"2023_CR14","doi-asserted-by":"publisher","first-page":"e9390","DOI":"10.1371\/journal.pone.0009390","volume":"5","author":"NM Archin","year":"2010","unstructured":"Archin, N. M. et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS ONE 5, e9390 (2010).","journal-title":"PLoS ONE"},{"key":"2023_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1310\/hct1306-301","volume":"13","author":"JP Routy","year":"2012","unstructured":"Routy, J. P. et al. Design and implementation of a randomized crossover study of valproic acid and antiretroviral therapy to reduce the HIV reservoir. HIV Clin. Trials 13, 301\u2013307 (2012).","journal-title":"HIV Clin. Trials"},{"key":"2023_CR16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","volume":"487","author":"NM Archin","year":"2012","unstructured":"Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482\u2013485 (2012).","journal-title":"Nature"},{"key":"2023_CR17","doi-asserted-by":"publisher","first-page":"e1004473","DOI":"10.1371\/journal.ppat.1004473","volume":"10","author":"JH Elliott","year":"2014","unstructured":"Elliott, J. H. et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 10, e1004473 (2014).","journal-title":"PLoS Pathog."},{"key":"2023_CR18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/infdis\/jiu155","volume":"210","author":"NM Archin","year":"2014","unstructured":"Archin, N. M. et al. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J. Infect. Dis. 210, 728\u2013735 (2014).","journal-title":"J. Infect. Dis."},{"key":"2023_CR19","doi-asserted-by":"publisher","first-page":"e1004071","DOI":"10.1371\/journal.ppat.1004071","volume":"10","author":"DG Wei","year":"2014","unstructured":"Wei, D. G. et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 10, e1004071 (2014).","journal-title":"PLoS Pathog."},{"key":"2023_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1586\/14787210.2016.1164031","volume":"14","author":"JD Gunst","year":"2016","unstructured":"Gunst, J. D., Tolstrup, M., Rasmussen, T. A. & S\u00f8gaard, O. S. The potential role for romidepsin as a component in early HIV-1 curative efforts. Expert Rev. Anti. Infect. Ther. 14, 447\u2013450 (2016).","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"2023_CR21","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/infdis\/jiaa777","volume":"224","author":"DK McMahon","year":"2021","unstructured":"McMahon, D. K. et al. A phase 1\/2 randomized, placebo-controlled trial of romidespin in persons with HIV-1 on suppressive antiretroviral therapy. J. Infect. Dis. 224, 648\u2013656 (2021).","journal-title":"J. Infect. Dis."},{"key":"2023_CR22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","volume":"36","author":"L Shan","year":"2012","unstructured":"Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491\u2013501 (2012).","journal-title":"Immunity"},{"key":"2023_CR23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3389\/fimmu.2020.00823","volume":"11","author":"B Mothe","year":"2020","unstructured":"Mothe, B. et al. HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: safety, immunogenicity and effect on the viral reservoir (Study BCN02). Front. Immunol. 11, 823 (2020).","journal-title":"Front. Immunol."},{"key":"2023_CR24","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S0140-6736(19)32990-3","volume":"395","author":"S Fidler","year":"2020","unstructured":"Fidler, S. et al. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet 395, 888\u2013898 (2020).","journal-title":"Lancet"},{"key":"2023_CR25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","volume":"25","author":"M Caskey","year":"2019","unstructured":"Caskey, M., Klein, F. & Nussenzweig, M. C. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat. Med. 25, 547\u2013553 (2019).","journal-title":"Nat. Med."},{"key":"2023_CR26","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1126\/science.aaf1279","volume":"352","author":"C-L Lu","year":"2016","unstructured":"Lu, C.-L. et al. Enhanced clearance of HIV-1\u2013infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352, 1001\u20131004 (2016).","journal-title":"Science"},{"key":"2023_CR27","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41467-022-28307-7","volume":"13","author":"J Dufloo","year":"2022","unstructured":"Dufloo, J. et al. Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells. Nat. Commun. 13, 630 (2022).","journal-title":"Nat. Commun."},{"key":"2023_CR28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1126\/science.aaf0972","volume":"352","author":"T Schoofs","year":"2016","unstructured":"Schoofs, T. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352, 997\u20131001 (2016).","journal-title":"Science"},{"key":"2023_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","volume":"26","author":"J Niessl","year":"2020","unstructured":"Niessl, J. et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nat. Med. 26, 222\u2013227 (2020).","journal-title":"Nat. Med."},{"key":"2023_CR30","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1126\/science.1207227","volume":"333","author":"JF Scheid","year":"2011","unstructured":"Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633\u20131637 (2011).","journal-title":"Science"},{"key":"2023_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature21435","volume":"543","author":"Y Nishimura","year":"2017","unstructured":"Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559\u2013563 (2017).","journal-title":"Nature"},{"key":"2023_CR32","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cell.2015.04.016","volume":"161","author":"DJ DiLillo","year":"2015","unstructured":"DiLillo, D. J. & Ravetch, J. V. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 161, 1035\u20131045 (2015).","journal-title":"Cell"},{"key":"2023_CR33","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/infdis\/jiab487","volume":"225","author":"CL Gay","year":"2022","unstructured":"Gay, C. L. et al. Stable latent HIV infection and low-level viremia despite treatment with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent vorinostat. J. Infect. Dis. 225, 856\u2013861 (2022).","journal-title":"J. Infect. Dis."},{"key":"2023_CR34","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/QAD.0000000000001524","volume":"31","author":"JD Gunst","year":"2017","unstructured":"Gunst, J. D., Tolstrup, M. & S\u00f8gaard, O. S. Beyond antiretroviral therapy: early interventions to control HIV-1 infection. AIDS 31, 1665\u20131667 (2017).","journal-title":"AIDS"},{"key":"2023_CR35","doi-asserted-by":"publisher","first-page":"e1002615","DOI":"10.1371\/journal.ppat.1002615","volume":"8","author":"J Reece","year":"2012","unstructured":"Reece, J. et al. An \u2018escape clock\u2019 for estimating the turnover of SIV DNA in resting CD4+ T cells. PLoS Pathog. 8, e1002615 (2012).","journal-title":"PLoS Pathog."},{"key":"2023_CR36","doi-asserted-by":"publisher","first-page":"e93330","DOI":"10.1371\/journal.pone.0093330","volume":"9","author":"JC Reece","year":"2014","unstructured":"Reece, J. C. et al. Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapies. PLoS ONE 9, e93330 (2014).","journal-title":"PLoS ONE"},{"key":"2023_CR37","doi-asserted-by":"publisher","first-page":"14050","DOI":"10.1128\/JVI.01701-14","volume":"88","author":"J Petravic","year":"2014","unstructured":"Petravic, J., Martyushev, A., Reece, J. C., Kent, S. J. & Davenport, M. P. Modeling the timing of antilatency drug administration during HIV treatment. J. Virol. 88, 14050\u201314056 (2014).","journal-title":"J. Virol."},{"key":"2023_CR38","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/nprot.2017.079","volume":"12","author":"AE Baxter","year":"2017","unstructured":"Baxter, A. E. et al. Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique. Nat. Protoc. 12, 2029\u20132049 (2017).","journal-title":"Nat. Protoc."},{"key":"2023_CR39","doi-asserted-by":"publisher","first-page":"e0056021","DOI":"10.1128\/mBio.00560-21","volume":"12","author":"MC Puertas","year":"2021","unstructured":"Puertas, M. C. et al. VIP-SPOT: an innovative assay to quantify the productive HIV-1 reservoir in the monitoring of cure strategies. mBio 12, e0056021 (2021).","journal-title":"mBio"},{"key":"2023_CR40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","volume":"566","author":"KM Bruner","year":"2019","unstructured":"Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 566, 120\u2013125 (2019).","journal-title":"Nature"},{"key":"2023_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20442-3","volume":"12","author":"NN Kinloch","year":"2021","unstructured":"Kinloch, N. N. et al. HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). Nat. Commun. 12, 165 (2021).","journal-title":"Nat. Commun."},{"key":"2023_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487\u2013491 (2015).","journal-title":"Nature"},{"key":"2023_CR43","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","volume":"24","author":"Y Bar-On","year":"2018","unstructured":"Bar-On, Y. et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat. Med. 24, 1701\u20131707 (2018).","journal-title":"Nat. Med."},{"key":"2023_CR44","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","volume":"27","author":"KE Stephenson","year":"2021","unstructured":"Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat. Med. 27, 1718\u20131724 (2021).","journal-title":"Nat. Med."},{"key":"2023_CR45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185\u2013191 (2017).","journal-title":"Nat. Med."},{"key":"2023_CR46","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1136\/bmj.l4179","volume":"366","author":"Q Feng","year":"2019","unstructured":"Feng, Q. et al. Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. Br. Med. J. 366, 4179 (2019).","journal-title":"Br. Med. J."},{"key":"2023_CR47","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/QAI.0000000000000111","volume":"66","author":"M Markowitz","year":"2014","unstructured":"Markowitz, M. et al. A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 66, 140\u2013147 (2014).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"2023_CR48","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1126\/science.1207227","volume":"333","author":"JF Scheid","year":"2011","unstructured":"Scheid, J. F. et al. Sequence and structural convergence. Science 333, 1633\u20131637 (2011).","journal-title":"Science"},{"key":"2023_CR49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/vaccines7030074","volume":"7","author":"K Stefic","year":"2019","unstructured":"Stefic, K., Bouvin-Pley, M., Braibant, M. & Barin, F. Impact of HIV-1 diversity on its sensitivity to neutralization. Vaccines 7, 74 (2019).","journal-title":"Vaccines"},{"key":"2023_CR50","doi-asserted-by":"publisher","first-page":"18002","DOI":"10.1073\/pnas.2008190117","volume":"117","author":"P Wang","year":"2020","unstructured":"Wang, P. et al. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti\u2013HIV-1 IgG1 antibodies in vivo. Proc. Natl Acad. Sci. USA 117, 18002\u201318009 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2023_CR51","doi-asserted-by":"publisher","first-page":"18754","DOI":"10.1073\/pnas.2008236117","volume":"117","author":"M Asokan","year":"2020","unstructured":"Asokan, M. et al. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proc. Natl Acad. Sci. USA 117, 18754\u201318763 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2023_CR52","doi-asserted-by":"publisher","first-page":"708355","DOI":"10.3389\/fimmu.2021.708355","volume":"12","author":"RT Veenhuis","year":"2021","unstructured":"Veenhuis, R. T., Garliss, C. C., Bailey, J. R. & Blankson, J. N. CD8 effector T cells function synergistically with broadly neutralizing antibodies to enhance suppression of HIV infection. Front. Immunol. 12, 708355 (2021).","journal-title":"Front. Immunol."},{"key":"2023_CR53","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41467-022-28250-7","volume":"13","author":"DA Spencer","year":"2022","unstructured":"Spencer, D. A. et al. Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis. Nat. Commun. 13, 662 (2022).","journal-title":"Nat. Commun."},{"key":"2023_CR54","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","volume":"15","author":"N Chomont","year":"2009","unstructured":"Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893\u2013900 (2009).","journal-title":"Nat. Med."},{"key":"2023_CR55","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.celrep.2017.09.081","volume":"21","author":"B Hiener","year":"2017","unstructured":"Hiener, B. et al. Identification of genetically intact HIV-1 proviruses in specific CD4+ T cells from effectively treated participants. Cell Rep. 21, 813\u2013822 (2017).","journal-title":"Cell Rep."},{"key":"2023_CR56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nm.3445","volume":"20","author":"MJ Buzon","year":"2014","unstructured":"Buzon, M. J. et al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat. Med. 20, 139\u2013142 (2014).","journal-title":"Nat. Med."},{"key":"2023_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6407","volume":"5","author":"S Jaafoura","year":"2014","unstructured":"Jaafoura, S. et al. Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4+ memory T cells. Nat. Commun. 5, 5407 (2014).","journal-title":"Nat. Commun."},{"key":"2023_CR58","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-020-0274-9","volume":"20","author":"DR Collins","year":"2020","unstructured":"Collins, D. R., Gaiha, G. D. & Walker, B. D. CD8+ T cells in HIV control, cure and prevention. Nat. Rev. Immunol. 20, 471\u2013482 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2023_CR59","unstructured":"Ros\u00e1s-Umbert, M. et al. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity. Nat. Commun. (in the press)."},{"key":"2023_CR60","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).","journal-title":"Nature"},{"key":"2023_CR61","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","volume":"27","author":"SG Deeks","year":"2021","unstructured":"Deeks, S. G. et al. Research priorities for an HIV cure: International AIDS Society global scientific strategy 2021. Nat. Med. 27, 2085\u20132098 (2021).","journal-title":"Nat. Med."},{"key":"2023_CR62","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/nm.4411","volume":"23","author":"JD Estes","year":"2017","unstructured":"Estes, J. D. et al. Defining total-body AIDS-virus burden with implications for curative strategies. Nat. Med. 23, 1271\u20131276 (2017).","journal-title":"Nat. Med."},{"key":"2023_CR63","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","volume":"606","author":"C Gaebler","year":"2022","unstructured":"Gaebler, C. et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature 606, 368\u2013374 (2022).","journal-title":"Nature"},{"key":"2023_CR64","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1745-6215-11-32","volume":"11","author":"KF Schulz","year":"2010","unstructured":"Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Trials 11, 32 (2010).","journal-title":"Trials"},{"key":"2023_CR65","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A. et al. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377\u2013381 (2009).","journal-title":"J. Biomed. Inform."},{"key":"2023_CR66","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).","journal-title":"J. Biomed. Inform."},{"key":"2023_CR67","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.chom.2016.07.015","volume":"20","author":"AE Baxter","year":"2016","unstructured":"Baxter, A. E. et al. Single-cell characterization of viral translation-competent reservoirs in HIV-infected individuals. Cell Host Microbe 20, 368\u2013380 (2016).","journal-title":"Cell Host Microbe"},{"key":"2023_CR68","doi-asserted-by":"publisher","first-page":"e00876-17","DOI":"10.1128\/mBio.00876-17","volume":"8","author":"J Grau-Exp\u00f3sito","year":"2017","unstructured":"Grau-Exp\u00f3sito, J. et al. A novel single-cell FISH-flow assay identifies effector memory CD4+ T cells as a major niche for HIV-1 transcription in HIV-infected patients. mBio 8, e00876-17 (2017).","journal-title":"mBio"},{"key":"2023_CR69","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1084\/jem.20190896","volume":"216","author":"C Gaebler","year":"2019","unstructured":"Gaebler, C. et al. Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. J. Exp. Med. 216, 2253\u20132264 (2019).","journal-title":"J. Exp. Med."},{"key":"2023_CR70","unstructured":"Parekh, B. S. et al. Performance evaluation of Asante rapid recency assay for HIV diagnosis and detection of recent infection: potential for surveillance and prevention. In: Ninth IAS Conference on HIV Science (2017)."},{"key":"2023_CR71","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1016\/S2352-3018(19)30052-9","volume":"6","author":"B Julg","year":"2019","unstructured":"Julg, B. et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials\u2014report of a consensus meeting. Lancet HIV 6, e259\u2013e268 (2019).","journal-title":"Lancet HIV"},{"key":"2023_CR72","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/cid\/ciu585","volume":"59","author":"GJ Besson","year":"2014","unstructured":"Besson, G. J. et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin. Infect. Dis. 59, 1312\u20131321 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"2023_CR73","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/1536867X0900900308","volume":"9","author":"P Royston","year":"2009","unstructured":"Royston, P. Multiple imputation of missing values: further update of ice, with an emphasis on categorical variables. Stata J. 9, 466\u2013477 (2009).","journal-title":"Stata J."},{"key":"2023_CR74","unstructured":"Rubin D. B. Multiple Imputation for Nonresponse in Surveys (Wiley, 2004)."},{"key":"2023_CR75","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.cjca.2020.11.010","volume":"37","author":"PC Austin","year":"2021","unstructured":"Austin, P. C., White, I. R., Lee, D. S. & van Buuren, S. Missing data in clinical research: a tutorial on multiple imputation. Can. J. Cardiol. 37, 1322\u20131331 (2021).","journal-title":"Can. J. Cardiol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02023-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02023-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02023-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:02:43Z","timestamp":1746622963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02023-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":75,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2023"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-02023-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]},"assertion":[{"value":"15 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published, the URL embedded in the clinical trial ID","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NCT03041012","URL":"https:\/\/doi.org\/https:\/\/clinicaltrials.gov\/study\/NCT03041012","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"was incorrect and has now been amended in the HTML and PDF versions of the article.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.C.N. is listed as an inventor on patents for the antibody 3BNC117. J.D.R. and C.J.P. are employees of Labcorp-Monogram Biosciences. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}